Carcinotech has raised £4.2m of funding as it looks to expand into the US later this year.
The Edinburgh-based company’s Carcino3D technology enables the manufacture of 3D printed micro-tumours using cells derived from patient biopsies and blood samples, to precisely simulate the tumour microenvironment, accelerating ethical drug screening and the delivery of more effective cancer treatments.
Eos Advisory led the investment alongside the Investment Fund for Scotland, Scottish Enterprise, Old College Capital, Investing Women Angels, and existing investors TRICAPITAL, SIS Ventures, Gabriel Investment Syndicate and Alba Equity.
It is also the first equity deal from the £150m Investment Fund for Scotland, through appointed fund managers Maven, on behalf of the British Business Bank.
Read more HERE.
